Psma binding ligand-linker conjugates and methods for using

Abstract

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

What is claimed is: 
     
         1 . A composition comprising a ligand of prostate specific membrane antigen (PSMA) (B), a linker (L), and a drug (D), wherein the linker is covalently bound to the drug and the linker is covalently bound to the ligand, and where the linker comprises a chain of at least seven atoms. 
     
     
         2 . A compound of the formula
   B-L-IA   
       or a salt thereof, wherein
 B is a ligand of prostate specific membrane antigen (PSMA) that is a urea of two amino acids, wherein the two amino acids are independently selected from asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, threonine and combinations thereof; 
 L is a divalent linker of 1 to 30 atoms in length, the divalent linker comprising a divalent carbonylalkylcarbonyl group and a divalent aminoalkylcarboxylate; and 
 IA is an optical imaging agent.